Surveillance biopsy timing not tied to reclassification
(HealthDay)—Timing of the first active surveillance biopsy is not associated with increased adverse reclassification of prostate cancer, according to a study published in the April issue of The Journal of Urology.
Apr 22, 2017
0
0